Alex G Raman1, Karthik V Sarma1,2, Steven S Raman2, Alan M Priester2,3, Sohrab Afshari Mirak2, Hannah H Riskin-Jones2, Nikhil Dhinagar1,2, William Speier1,2, Ely Felker2, Anthony E Sisk4, David Lu2, Adam Kinnaird5,6, Robert E Reiter5, Leonard S Marks5, Corey W Arnold1,2,3,4. 1. Computational Diagnostics Lab, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. 2. Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. 3. Department of Bioengineering, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. 4. Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. 5. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. 6. Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.
Abstract
PURPOSE: The appropriate number of systematic biopsy cores to retrieve during magnetic resonance imaging (MRI)-targeted prostate biopsy is not well defined. We aimed to demonstrate a biopsy sampling approach that reduces required core count while maintaining diagnostic performance. MATERIALS AND METHODS: We collected data from a cohort of 971 men who underwent MRI-ultrasound fusion targeted biopsy for suspected prostate cancer. A regional targeted biopsy (RTB) was evaluated retrospectively; only cores within 2 cm of the margin of a radiologist-defined region of interest were considered part of the RTB. We compared detection rates for clinically significant prostate cancer (csPCa) and cancer upgrading rate on final whole mount pathology after prostatectomy between RTB, combined, MRI-targeted, and systematic biopsy. RESULTS: A total of 16,459 total cores from 971 men were included in the study data sets, of which 1,535 (9%) contained csPCa. The csPCa detection rates for systematic, MRI-targeted, combined, and RTB were 27.0% (262/971), 38.3% (372/971), 44.8% (435/971), and 44.0% (427/971), respectively. Combined biopsy detected significantly more csPCa than systematic and MRI-targeted biopsy (p <0.001 and p=0.004, respectively) but was similar to RTB (p=0.71), which used on average 3.8 (22%) fewer cores per patient. In 102 patients who underwent prostatectomy, there was no significant difference in upgrading rates between RTB and combined biopsy (p=0.84). CONCLUSIONS: A RTB approach can maintain state-of-the-art detection rates while requiring fewer retrieved cores. This result informs decision making about biopsy site selection and total retrieved core count.
PURPOSE: The appropriate number of systematic biopsy cores to retrieve during magnetic resonance imaging (MRI)-targeted prostate biopsy is not well defined. We aimed to demonstrate a biopsy sampling approach that reduces required core count while maintaining diagnostic performance. MATERIALS AND METHODS: We collected data from a cohort of 971 men who underwent MRI-ultrasound fusion targeted biopsy for suspected prostate cancer. A regional targeted biopsy (RTB) was evaluated retrospectively; only cores within 2 cm of the margin of a radiologist-defined region of interest were considered part of the RTB. We compared detection rates for clinically significant prostate cancer (csPCa) and cancer upgrading rate on final whole mount pathology after prostatectomy between RTB, combined, MRI-targeted, and systematic biopsy. RESULTS: A total of 16,459 total cores from 971 men were included in the study data sets, of which 1,535 (9%) contained csPCa. The csPCa detection rates for systematic, MRI-targeted, combined, and RTB were 27.0% (262/971), 38.3% (372/971), 44.8% (435/971), and 44.0% (427/971), respectively. Combined biopsy detected significantly more csPCa than systematic and MRI-targeted biopsy (p <0.001 and p=0.004, respectively) but was similar to RTB (p=0.71), which used on average 3.8 (22%) fewer cores per patient. In 102 patients who underwent prostatectomy, there was no significant difference in upgrading rates between RTB and combined biopsy (p=0.84). CONCLUSIONS: A RTB approach can maintain state-of-the-art detection rates while requiring fewer retrieved cores. This result informs decision making about biopsy site selection and total retrieved core count.
Authors: Alan Priester; Shyam Natarajan; Pooria Khoshnoodi; Daniel J Margolis; Steven S Raman; Robert E Reiter; Jiaoti Huang; Warren Grundfest; Leonard S Marks Journal: J Urol Date: 2016-07-30 Impact factor: 7.450
Authors: Stephan Tschirdewahn; Manuel Wiesenfarth; David Bonekamp; Lukas Püllen; Henning Reis; Andrej Panic; Claudia Kesch; Christopher Darr; Jochen Heß; Francesco Giganti; Caroline M Moore; Nika Guberina; Michael Forsting; Axel Wetter; Boris Hadaschik; Jan Philipp Radtke Journal: Eur Urol Focus Date: 2020-07-11
Authors: Jonathan I Epstein; Lars Egevad; Mahul B Amin; Brett Delahunt; John R Srigley; Peter A Humphrey Journal: Am J Surg Pathol Date: 2016-02 Impact factor: 6.394
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford Journal: Eur Urol Date: 2016-08-25 Impact factor: 20.096
Authors: Geoffrey A Sonn; Shyam Natarajan; Daniel J A Margolis; Malu MacAiran; Patricia Lieu; Jiaoti Huang; Frederick J Dorey; Leonard S Marks Journal: J Urol Date: 2012-11-14 Impact factor: 7.450
Authors: Christopher P Filson; Shyam Natarajan; Daniel J A Margolis; Jiaoti Huang; Patricia Lieu; Frederick J Dorey; Robert E Reiter; Leonard S Marks Journal: Cancer Date: 2016-01-07 Impact factor: 6.860
Authors: Veeru Kasivisvanathan; Antti S Rannikko; Marcelo Borghi; Valeria Panebianco; Lance A Mynderse; Markku H Vaarala; Alberto Briganti; Lars Budäus; Giles Hellawell; Richard G Hindley; Monique J Roobol; Scott Eggener; Maneesh Ghei; Arnauld Villers; Franck Bladou; Geert M Villeirs; Jaspal Virdi; Silvan Boxler; Grégoire Robert; Paras B Singh; Wulphert Venderink; Boris A Hadaschik; Alain Ruffion; Jim C Hu; Daniel Margolis; Sébastien Crouzet; Laurence Klotz; Samir S Taneja; Peter Pinto; Inderbir Gill; Clare Allen; Francesco Giganti; Alex Freeman; Stephen Morris; Shonit Punwani; Norman R Williams; Chris Brew-Graves; Jonathan Deeks; Yemisi Takwoingi; Mark Emberton; Caroline M Moore Journal: N Engl J Med Date: 2018-03-18 Impact factor: 176.079
Authors: Chad R Tracy; Kevin J Flynn; Daniel D Sjoberg; Paul T Gellhaus; Catherine M Metz; Behfar Ehdaie Journal: Urol Oncol Date: 2020-10-27 Impact factor: 2.954
Authors: Marinus J Hagens; Mar Fernandez Salamanca; Anwar R Padhani; Pim J van Leeuwen; Henk G van der Poel; Ivo G Schoots Journal: Eur Urol Open Sci Date: 2022-05-02